Pediatric glioblastomas and passive degranulation immunotherapy

Pediatric glioblastoma is among the most aggressive and deadly brain tumors, with current therapies providing limited efficacy and poor long-term survival. Recent advances in AllergoOncology have introduced targeted passive degranulation immunotherapy (TPDI), a promising approach that leverages human immunoglobulin E monoclonal antibodies (hIgE mAbs) to induce localized degranulation and stimulate anti-glioblastoma inflammation. TPDI entails the intratumoral administration of hIgE mAbs—sourced from atopic donors or produced through recombinant technology—followed by the precise delivery of the relevant allergen directly into the glioblastoma microenvironment. Of relevance are polyploid giant cancer cells (PGCCs), a highly aggressive and therapy-resistant subpopulation implicated in glioblastoma progression and recurrence. This review explores the potential of TPDI to disrupt glioblastoma-associated PGCCs to improve survival outcomes in pediatric patients.